At the pre-OMZ baseline (immediately before first injection), total IgE was above the laboratory upper limit of normal in all 25/25 patients; by week 12, it declined in 23/25 (92%), whereas 2/25 showed an increase yet nonetheless improved clinically; taken together, IgE dynamics broadly paralleled the mean 6.2-point reduction in VAS–pruritus and the ~105-point fall in BPDAI, suggesting that early IgE decline often mirrors—but is not requisite for—symptom relief and objective disease control. Here, IGHE is linked to Pruritus.